NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer

NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer

The property of drug-resistance may attenuate clinical therapy in cancer cells, such as chemoresistance to gefitinib in colon cancer cells. In previous studies, overexpression of PD-L1 causes proliferation and metastasis in cancer cells; therefore, the PD-L1 pathway allows tumor cells to exert an ad...

Full description

Bibliographic Details
Main Authors: Tung-Yung Huang, Tung-Cheng Chang, Yu-Tang Chin, Yi-Shin Pan, Wong-Jin Chang, Feng-Cheng Liu, Ema Dwi Hastuti, Shih-Jiuan Chiu, Shwu-Huey Wang, Chun A. Changou, Zi-Lin Li, Yi-Ru Chen, Hung-Ru Chu, Ya-Jung Shih, R. Holland Cheng, Alexander Wu, Hung-Yun Lin, Kuan Wang, Jacqueline Whang-Peng, Shaker A Mousa, Paul J. Davis
Format: Article
Language:English
Published: MDPI AG 2020-08-01
Series:Cells
Subjects:
Keywords: colorectal cancer (CRC), gefitinib
NDAT
PD-L1
PI3K
Online Access:https://www.mdpi.com/2073-4409/9/8/1830

Similar Items

Similar Items